article thumbnail

The Gains and Pains of Using AI in the Pharmaceutical Industry

HIT Consultant

Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most importantly the high failure rate. A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is DARWIN EU?

Healthcare ECONOMIST

By supporting decision-making on the development, authorisation and surveillance of medicines, a wide range of stakeholders will benefit, from patients and healthcare professionals to health technology assessment bodies and the pharmaceutical industry. Arlett et al. The DARWIN EU advisory board members are listed here.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division. Value Health. Kesselheim.

article thumbnail

Roundups: 16 Recent Strategic Digital Health Partnerships

HIT Consultant

The CCPC project aims to allow patients to continue their care at home after discharge through the development of new predictive analytics, AI, and home monitoring technology that integrates with current medical systems for uninterrupted care from hospital to home. FIGS, Inc. ,

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Kesselheim Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues. By  Ameet Sarpatwari , Alexander Egilman , and   Aaron S. JAMA Netw Open. Lancet Oncol.

article thumbnail

Mortal Sins of Orphan Drug Development: How to Save the Lost Souls

Bill Of Health

In a working paper from November 2020 , the EU Commission finds a significant inefficiency in the EU orphan drug regulation (a pan-EU piece of legislation): that it does not contain a provision to safeguard the affordability and accessibility of orphan medicines. But, is the orphan drug regulation the right place for this type of law?